CA3204383A1 - Thienyl and cycloalkyl aminopyrimidine compounds as inhibitors of nuak kinases, compositions and uses thereof - Google Patents
Thienyl and cycloalkyl aminopyrimidine compounds as inhibitors of nuak kinases, compositions and uses thereofInfo
- Publication number
- CA3204383A1 CA3204383A1 CA3204383A CA3204383A CA3204383A1 CA 3204383 A1 CA3204383 A1 CA 3204383A1 CA 3204383 A CA3204383 A CA 3204383A CA 3204383 A CA3204383 A CA 3204383A CA 3204383 A1 CA3204383 A1 CA 3204383A1
- Authority
- CA
- Canada
- Prior art keywords
- amino
- 6a1ky1
- carboxamide
- difluoromethoxy
- thiophene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163134739P | 2021-01-07 | 2021-01-07 | |
| US63/134,739 | 2021-01-07 | ||
| PCT/CA2022/050014 WO2022147620A1 (en) | 2021-01-07 | 2022-01-07 | Thienyl and cycloalkyl aminopyrimidine compounds as inhibitors of nuak kinases, compositions and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3204383A1 true CA3204383A1 (en) | 2022-07-14 |
Family
ID=82356983
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3204383A Pending CA3204383A1 (en) | 2021-01-07 | 2022-01-07 | Thienyl and cycloalkyl aminopyrimidine compounds as inhibitors of nuak kinases, compositions and uses thereof |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240025887A1 (enExample) |
| EP (1) | EP4274829A4 (enExample) |
| JP (1) | JP2024502174A (enExample) |
| CN (1) | CN116981664A (enExample) |
| AU (1) | AU2022205713A1 (enExample) |
| CA (1) | CA3204383A1 (enExample) |
| WO (1) | WO2022147620A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116903591B (zh) * | 2023-07-13 | 2025-08-26 | 特科罗生物科技(成都)有限公司 | 一种嘧啶胺类nuak抑制剂及其制备方法和用途 |
| CN116903592B (zh) * | 2023-07-13 | 2025-08-01 | 特科罗生物科技(成都)有限公司 | 一种嘧啶胺类nuak抑制剂及其制备方法和用途 |
| CN116947764B9 (zh) * | 2023-07-13 | 2025-07-25 | 特科罗生物科技(成都)有限公司 | 一种嘧啶胺类nuak抑制剂及其制备方法和用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7754714B2 (en) * | 2004-05-18 | 2010-07-13 | Rigel Pharmaceuticals, Inc. | Cycloalkyl substituted pyrimidinediamine compounds and their uses |
| US20060270694A1 (en) * | 2005-05-03 | 2006-11-30 | Rigel Pharmaceuticals, Inc. | JAK kinase inhibitors and their uses |
| RS20080272A (sr) * | 2005-12-21 | 2009-07-15 | Pfizer Products Inc., | Derivati pirimidina za tretman neprirodnog rasta ćelija |
| CA2648170A1 (en) * | 2006-04-10 | 2007-10-18 | Boehringer Ingelheim International Gmbh | 2, 4-diaminopyrimidine derivatives and their use for the treatment of cancer |
| ES2555803T3 (es) * | 2006-10-23 | 2016-01-08 | Cephalon, Inc. | Fusión de derivados bicíclicos 2,4-diaminopirimidina como utilizar inhibidores ALK y c-Met |
| CA2673184A1 (en) * | 2006-12-22 | 2008-07-03 | Boehringer Ingelheim International Gmbh | New compounds |
| WO2009032668A2 (en) * | 2007-08-28 | 2009-03-12 | Irm Llc | 2 -biphenylamino-4 -aminopyrimidine derivatives as kinase inhibitors |
| EP2300013B2 (en) * | 2008-05-21 | 2024-11-13 | Takeda Pharmaceutical Company Limited | Phosphorous derivatives as kinase inhibitors |
| US20140024620A1 (en) * | 2010-10-14 | 2014-01-23 | Ariad Pharmaceuticals, Inc. | Methods for Inhibiting Cell Proliferation in EGFR-Driven Cancers |
| CN110724137B (zh) * | 2019-11-13 | 2021-03-30 | 广东工业大学 | 一种噻吩类衍生物及其制备方法与应用 |
-
2022
- 2022-01-07 JP JP2023541657A patent/JP2024502174A/ja active Pending
- 2022-01-07 CA CA3204383A patent/CA3204383A1/en active Pending
- 2022-01-07 WO PCT/CA2022/050014 patent/WO2022147620A1/en not_active Ceased
- 2022-01-07 EP EP22736479.1A patent/EP4274829A4/en not_active Withdrawn
- 2022-01-07 AU AU2022205713A patent/AU2022205713A1/en not_active Abandoned
- 2022-01-07 US US18/271,089 patent/US20240025887A1/en active Pending
- 2022-01-07 CN CN202280019540.7A patent/CN116981664A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022147620A1 (en) | 2022-07-14 |
| EP4274829A4 (en) | 2024-12-11 |
| US20240025887A1 (en) | 2024-01-25 |
| EP4274829A1 (en) | 2023-11-15 |
| CN116981664A (zh) | 2023-10-31 |
| JP2024502174A (ja) | 2024-01-17 |
| AU2022205713A1 (en) | 2023-07-27 |
| AU2022205713A9 (en) | 2025-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2947338C (en) | Multi-fluoro-substituted compound as bruton's tyrosine kinase (btk) inhibitor | |
| CN111153899B (zh) | 一种取代吡啶化合物、其制备方法和用途 | |
| EP3080125B1 (en) | Novel azaindole derivatives as selective histone deacetylase (hdac) inhibitors and pharmaceutical compositions comprising the same | |
| US20240092763A1 (en) | Isoindolinone aminopyrimidine compounds as inhibitors of nuak kinases, compositions and uses thereof | |
| CA3073977A1 (en) | Inhibitors of wdr5 protein-protein binding | |
| US20240025887A1 (en) | Thienyl and cycloalkyl aminopyrimidine compounds as inhibitors of nuak kinases, compositions and uses thereof | |
| CA3130456A1 (en) | Heterotricyclic derivative compound and use of same | |
| TW200927128A (en) | Novel protein kinase B inhibitors | |
| WO2017090002A2 (en) | Inhibitors of pi3 kinases | |
| WO2019119145A1 (en) | Tricyclic inhibitors of the bcl6 btb domain protein-protein interaction and uses thereof | |
| CA3189873A1 (en) | 1h-benzo[d]imidazole derivatives as tlr9 inhibitors for the treatment of fibrosis | |
| US12606533B2 (en) | 3-phenylpropylamine derivative | |
| Xiong et al. | Development of potent NEDD8-activating enzyme inhibitors bearing a pyrimidotriazole scaffold | |
| NZ568014A (en) | Substituted bicyclic pyrimidone derivatives | |
| CN104470922B (zh) | 药物活性化合物 | |
| EP3728248B1 (en) | Azaindole derivatives as rho-kinase inhibitors | |
| CA3225596A1 (en) | Inhibitors targeting ubiquitin specific protease 7 (usp7) | |
| EP3679039B1 (en) | Tyrosine analogues derivatives as rho- kinase inhibitors | |
| FR2940285A1 (fr) | Derives de 6-cycloamino-2-thienyl-3-(pyridin-4-yl)imidazo °1,2-b!-pyridazine et 6-cycloamino-2-furanyl-3- (pyridin-4-yl)imidazo°1,2-b!-pyridazine, leur preparation et leur application en therapeutique | |
| TWI572608B (zh) | 雙環雜環衍生物、其製備方法及醫療用途 | |
| KR20250173569A (ko) | 세포 상태 표적화 기술 | |
| CN113121524B (zh) | 杂环亚砜亚胺化合物及其中间体、制备方法和应用 | |
| CN111848605B (zh) | 一种取代吡啶并[3,4-b]吡嗪-2(1H)-酮化合物、其制备方法和用途 | |
| EP4396191B1 (en) | Compounds useful in modulation of ahr signalling | |
| EP4182322B1 (en) | Pyrido oxazine derivatives as alk5 inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241206 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241206 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241206 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251111 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251111 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260428 |